Company
VectivBio Holding AG
Headquarters: Basel, Switzerland
CEO: Dr. Luca Santarelli M.D.
Market Cap
$474.9 Million
USD as of Jan. 1, 2023
VectivBio Holding AG Categories
Switzerland
languages
Healthcare
languages
Biotechnology
Switzerland Healthcare
Switzerland Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
Novo Nordisk
|
$329.83 B |
Vertex Pharmaceuticals Incorporated
|
$88.79 B |
CSL Limited
|
$85.00 B |
| Marinomed Biotech AG | $84.73 B |
|
Regeneron Pharmaceuticals, Inc.
|
$78.88 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$428.70 B |
|
Lilly
|
$417.05 B |
|
Johnson & Johnson
|
$412.24 B |
|
Novo Nordisk
|
$329.83 B |
|
Merck
|
$275.82 B |
Detailed Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
Stocks & Indices
VectivBio Holding AG has the following listings and related stock indices.
Stock: NASDAQ: VECT